AstraZeneca Reports Phase 3 Data for Durvalumab in Hepatocellular carcinoma

AstraZeneca today announced Phase 3 results for durvalumab in patients with hepatocellular carcinoma. The study demonstrated that durvalumab significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of hepatocellular carcinoma and support the continued development of durvalumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.